S&P Futures
4,277.00 +0.25 (+0.01%) Dow Futures
33,966.00 +3.00 (+0.01%) Nasdaq Futures
13,490.25 -3.00 (-0.02%) Russell 2000 Futures
1,992.00 +2.90 (+0.15%) Crude Oil
89.45 +1.34 (+1.52%) Gold
1,780.20 +3.50 (+0.20%)
bluebird bio, Inc. (BLUE)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 6.58 |
| Open | 6.29 |
| Bid | 0.00 x 2200 |
| Ask | 0.00 x 900 |
| Day's Range | 6.12 - 8.18 |
| 52 Week Range | 2.87 - 17.85 |
| Volume | |
| Avg. Volume | 8,623,811 |
| Market Cap | 522.886M |
| Beta (5Y Monthly) | 1.33 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.43 |
| Earnings Date | Nov 03, 2022 - Nov 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for BLUE
Related Research
- bluebird bio, Inc.Analyst Report: Vertex Pharmaceuticals, Inc.Vertex Pharmaceuticals develops therapies to address cystic fibrosis and other diseases. The company was founded in 1989 in Cambridge, Massachusetts and has 3,500 employees. It has research programs and facilities in the U.S., the U.K., and Canada. The shares are a component of the S&P 500.RatingFair ValueEconomic Moat6 days agoArgus Research
- The Wall Street Journal
FDA Approves Bluebird’s $2.8 Million Gene Therapy for Rare Blood Disease
The FDA approved a first-of-its-kind treatment from Bluebird Bio that represents a potential cure for a rare blood disorder at a price of $2.8 million per patient.
- American City Business Journals
Bluebird bio nabs major win with first FDA approval following split
Somerville gene therapy firm bluebird bio Inc. has scored its first approval from the U.S. Food and Drug Administration following its business split late last year.
- Bluebird's $2.8 million gene therapy becomes most expensive drug after U.S. approvalReuters
- bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell TransfusionsBusiness Wire
- Business Wire
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
SOMERVILLE, Mass., August 17, 2022--Following the FDA approval of ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, for the treatment of beta-thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions, today bluebird bio released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, including an innovative, outcomes-based contract offering and a comprehensive patient support program.
